1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Merck & Co. Hits Target With Pneumococcal Vaccine, As Rivalry With Pfizer Continues

 
• By Alaric DeArment

The vaccine, V116, targets eight unique serotypes, and it is particularly geared toward preventing pneumococcal disease in adults, especially the elderly, according to Merck.

Merck announced positive results for its pneumococcal disease vaccine, V116 • Source: Shutterstock

Merck & Co., Inc. is looking to bring a new vaccine to market for the prevention of pneumococcal disease in adults, but the company will have to compete against Pfizer Inc., which has long been a rival in the market with its blockbuster Prevnar franchise. The company hopes the new vaccine could offer the broadest protection for adults. 

Merck is not new to competing against Pfizer in the pneumococcal space. The two are already facing off with Merck’s 15-valent vaccine Vaxneuvance and an older 23-valent pneumococcal polysaccharide vaccine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

More from Therapy Areas

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.